Futibatinib (TAS-120), a covalently-binding FGFR inhibitor, has received Breakthrough Therapy designation from FDA for patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
